Inapparent infiltrations associated with vindesine administration

Robert T Dorr, S. E. Jones

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Vindesine is des-acetyl vinblastine amide sulfate, an investigational derivative of the vinca alkaloid, vinblastine. Initial phase I results with vindesine have determined that myelotoxicity is dose-limiting and that, contrary to preclinical studies in animals, a neurotic potential is indeed present. Another phase I study also observed a rather high incidence of phlebitis (16%) and of cellulitis (10%), however, myelosuppresion remained the dose-limiting toxicity. Because good clinical responses have been noted in lymphomas, leukemias and some solid tumors including breast cancer, the drug has a potential for wide utility. However, while we have noted several clinical responses with vindesine, injections of the drug have been complicated by serious infilatration with atypically delayed presentation. The purpose of this communication is to briefly describe the incidence and course of these infiltrations.

Original languageEnglish (US)
Pages (from-to)285-288
Number of pages4
JournalMedical and Pediatric Oncology
Volume6
Issue number4
StatePublished - 1979

Fingerprint

Vindesine
Vinblastine
Vinca Alkaloids
Phlebitis
Cellulitis
Incidence
Amides
Pharmaceutical Preparations
Lymphoma
Leukemia
Breast Neoplasms
Injections
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pediatrics, Perinatology, and Child Health

Cite this

Inapparent infiltrations associated with vindesine administration. / Dorr, Robert T; Jones, S. E.

In: Medical and Pediatric Oncology, Vol. 6, No. 4, 1979, p. 285-288.

Research output: Contribution to journalArticle

@article{e78d4e80044c41d0bbec4e790cb9b1b2,
title = "Inapparent infiltrations associated with vindesine administration",
abstract = "Vindesine is des-acetyl vinblastine amide sulfate, an investigational derivative of the vinca alkaloid, vinblastine. Initial phase I results with vindesine have determined that myelotoxicity is dose-limiting and that, contrary to preclinical studies in animals, a neurotic potential is indeed present. Another phase I study also observed a rather high incidence of phlebitis (16{\%}) and of cellulitis (10{\%}), however, myelosuppresion remained the dose-limiting toxicity. Because good clinical responses have been noted in lymphomas, leukemias and some solid tumors including breast cancer, the drug has a potential for wide utility. However, while we have noted several clinical responses with vindesine, injections of the drug have been complicated by serious infilatration with atypically delayed presentation. The purpose of this communication is to briefly describe the incidence and course of these infiltrations.",
author = "Dorr, {Robert T} and Jones, {S. E.}",
year = "1979",
language = "English (US)",
volume = "6",
pages = "285--288",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Inapparent infiltrations associated with vindesine administration

AU - Dorr, Robert T

AU - Jones, S. E.

PY - 1979

Y1 - 1979

N2 - Vindesine is des-acetyl vinblastine amide sulfate, an investigational derivative of the vinca alkaloid, vinblastine. Initial phase I results with vindesine have determined that myelotoxicity is dose-limiting and that, contrary to preclinical studies in animals, a neurotic potential is indeed present. Another phase I study also observed a rather high incidence of phlebitis (16%) and of cellulitis (10%), however, myelosuppresion remained the dose-limiting toxicity. Because good clinical responses have been noted in lymphomas, leukemias and some solid tumors including breast cancer, the drug has a potential for wide utility. However, while we have noted several clinical responses with vindesine, injections of the drug have been complicated by serious infilatration with atypically delayed presentation. The purpose of this communication is to briefly describe the incidence and course of these infiltrations.

AB - Vindesine is des-acetyl vinblastine amide sulfate, an investigational derivative of the vinca alkaloid, vinblastine. Initial phase I results with vindesine have determined that myelotoxicity is dose-limiting and that, contrary to preclinical studies in animals, a neurotic potential is indeed present. Another phase I study also observed a rather high incidence of phlebitis (16%) and of cellulitis (10%), however, myelosuppresion remained the dose-limiting toxicity. Because good clinical responses have been noted in lymphomas, leukemias and some solid tumors including breast cancer, the drug has a potential for wide utility. However, while we have noted several clinical responses with vindesine, injections of the drug have been complicated by serious infilatration with atypically delayed presentation. The purpose of this communication is to briefly describe the incidence and course of these infiltrations.

UR - http://www.scopus.com/inward/record.url?scp=0018577438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018577438&partnerID=8YFLogxK

M3 - Article

C2 - 481319

AN - SCOPUS:0018577438

VL - 6

SP - 285

EP - 288

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 4

ER -